ADCT:NYE-ADC Therapeutics SA (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 4.71

Change

+0.30 (+6.80)%

Market Cap

USD 0.37B

Volume

0.40M

Analyst Target

USD 53.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-01 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NVO Novo Nordisk A/S

-1.62 (-1.20%)

USD 567.03B
RPRX Royalty Pharma Plc

-0.33 (-1.17%)

USD 16.78B
BHVN Biohaven Pharmaceutical Holdin..

+1.37 (+3.69%)

USD 3.27B
HTD John Hancock Tax Advantaged Di..

-0.02 (-0.10%)

USD 2.41B
DNA Ginkgo Bioworks Holdings

N/A

USD 1.68B
RCUS Arcus Biosciences Inc

-0.09 (-0.51%)

USD 1.41B
NUVB Nuvation Bio Inc

+0.11 (+3.33%)

USD 0.80B
PGP PIMCO Global StocksPLUS & Inco..

+0.04 (+0.53%)

USD 0.32B
ATNM Actinium Pharmaceuticals Inc

+0.12 (+1.23%)

USD 0.29B
CYBN Cybin Inc

N/A

USD 0.28B

ETFs Containing ADCT

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 183.73% 100% F 100% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 183.73% 100% F 100% F
Trailing 12 Months  
Capital Gain 146.60% 97% N/A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 146.60% 97% N/A 99% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -37.94% 11% F 1% F
Dividend Return -37.94% 11% F 1% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 45.05% 51% F 22% F
Risk Adjusted Return -84.21% 14% F 3% F
Market Capitalization 0.37B 83% B 41% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.